New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc.

HIND

Healthcare Biotechnology

Vyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.

Revenue
+67.6%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.20 0.25 −17.24%
Market cap
$10.2M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, Sep 30, 2026

It holds $6.6M more in cash and short-term investments than it owes in debt. Shareholders’ equity is 76.0% of the balance sheet. What is a balance sheet?

Sep 30, 2026 · total $8.6M

Owns

$1.0MLong-term assets
$641.6KOther short-term assets
$7.0MCash & short-term investments

Funded by

$6.5MShareholders’ equity
$1.7MOther liabilities
$344.2KDebt

Debt is 4.00% of the total; shareholders’ equity 76.0%.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Total current assets
7.60 8.15 9.16 5.44
Total non-current assets
1.01 1.02 1.02 1.06
Total Assets
8.61 9.18 10.19 6.50
Total current liabilities
2.07 1.86 2.14 2.74
Total non-current liabilities
— — — —
Total liabilities
2.07 1.86 2.14 2.74
Common Equity (Total)
6.55 7.31 8.04 3.76
Shareholders Equity (Total)
6.55 7.31 8.04 3.76
Total Debt
0.34 — — 0.25

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026